. Author manuscript; available in PMC: 2013 Jun 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2011 Dec 7;18(6):937–943. doi: 10.1016/j.bbmt.2011.11.024

Table 2.

Outcomes after allogeneic HCT (N = 24)

		N died	100 day survival	2 year survival
Survival		14	71% (53–89%)	40% (21–59%)

		N events	100 day LFS	2 year PFS
Leukemia-Free Survival		14	75% (53–88%)	40% (21–59%)

			100 day Relapse	2 year Relapse
Relapse/Progression		6	8% (0–19%)	26% (8–44%)

			100 day NRM	1 year NRM
Non-Relapse Mortality		8	17% (3–31%)	34% (15–53%)

Grade II–IV acute GVHD		8	34% (14–54%)
Maximum grade acute GVHD		N (%)
Grade	None	14 (58%)
	I	2 (8%)
	II	5 (21%)
	III	2 (8%)
	IV	1 (4%)
			1 year chronic GVHD

Chronic GVHD		4	20% (2–38%)

Shown are the number (%) and Kaplan Meier (survival, LFS) or cumulative incidence (Relapse, GVHD, NRM) estimates of post-HCT events (± 95% confidence intervals).